Literature DB >> 1320570

Regional distribution of beta 1- and beta 2-adrenoceptors in the failing and nonfailing human heart.

M Steinfath1, J Lavicky, W Schmitz, H Scholz, V Döring, P Kalmár.   

Abstract

Total beta-adrenoceptor density and beta 1- and beta 2-subtype distribution in right and left atria and in different ventricular regions from 14 failing and seven nonfailing human hearts have been compared. End-stage heart failure was due to idiopathic dilated cardiomyopathy (n = 8) or ischaemic cardiomyopathy (n = 6). In nonfailing hearts the total beta-adrenoceptor density was similar in the right and left atria and in all the ventricular regions studied (about 70 to 80 fmol/mg protein). The beta 1:beta 2-adrenoceptor ratio in both nonfailing atria was similar (about 70:30%) and was significantly smaller than in the different regions of both ventricles (about 80:20%). The beta 1-subtype density was similar in nonfailing atria and ventricles (about 55 fmol/mg protein). The beta 2-subtype density was significantly higher in the right and left atrium (about 25 fmol/mg protein) than in both ventricles (about 15 fmol/mg protein). In patients with end-stage heart failure due to idiopathic dilated cardiomyopathy or ischaemic cardiomyopathy the total beta-adrenoceptor density was reduced by 50-60% in all regions. On the other hand, the beta 1- and beta 2-subtype distribution differed with the cause of heart failure. In patients with idiopathic dilated cardiomyopathy, the beta 1-adrenoceptor density was not significantly reduced. In patients with ischaemic cardiomyopathy both beta 1- and beta 2-adrenoceptors were reduced in all regions. It is concluded that downregulation of beta-adrenoceptors in patients with end-stage idiopathic dilated cardiomyopathy or ischaemic cardiomyopathy occurs uniformly throughout the heart. The results support the hypothesis that changes in beta-adrenoceptor subtypes may be related to the cause of heart failure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320570     DOI: 10.1007/bf00265923

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Selective regulation of beta 1- and beta 2-adrenoceptors in the human heart by chronic beta-adrenoceptor antagonist treatment.

Authors:  M C Michel; A Pingsmann; J J Beckeringh; H R Zerkowski; N Doetsch; O E Brodde
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

Review 2.  In vivo studies on the function of cardiac beta-adrenoceptors in man.

Authors:  D G McDevitt
Journal:  Eur Heart J       Date:  1989-06       Impact factor: 29.983

3.  CGP 20712 A: a useful tool for quantitating beta 1- and beta 2-adrenoceptors.

Authors:  D J Dooley; H Bittiger; N C Reymann
Journal:  Eur J Pharmacol       Date:  1986-10-14       Impact factor: 4.432

4.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.

Authors:  M R Bristow; R Ginsburg; V Umans; M Fowler; W Minobe; R Rasmussen; P Zera; R Menlove; P Shah; S Jamieson
Journal:  Circ Res       Date:  1986-09       Impact factor: 17.367

5.  Reduced effects of dopexamine on force of contraction in the failing human heart despite preserved beta 2-adrenoceptor subpopulation.

Authors:  M Böhm; B Pieske; P Schnabel; R Schwinger; B Kemkes; W P Klövekorn; E Erdmann
Journal:  J Cardiovasc Pharmacol       Date:  1989-10       Impact factor: 3.105

6.  Relations between beta-adrenoceptor occupancy and increases of contractile force and adenylate cyclase activity induced by catecholamines in human ventricular myocardium. Acute desensitization and comparison with feline ventricle.

Authors:  A J Kaumann; H Lemoine; U Schwederski-Menke; B Ehle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989 Jan-Feb       Impact factor: 3.000

7.  Coexistence and localization of beta 1- and beta 2-adrenoceptors in the human heart.

Authors:  R J Summers; P Molnaar; F Russell; J Elnatan; C R Jones; B F Buxton; V Chang; J Hambley
Journal:  Eur Heart J       Date:  1989-06       Impact factor: 29.983

8.  Human cardiac beta-adrenoceptors: both beta 1- and beta 2-adrenoceptors are functionally coupled to the adenylate cyclase in right atrium.

Authors:  O E Brodde; N O'Hara; H R Zerkowski; N Rohm
Journal:  J Cardiovasc Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.105

9.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

10.  Chronic beta 1-adrenoceptor antagonist treatment sensitizes beta 2-adrenoceptors, but desensitizes M2-muscarinic receptors in the human right atrium.

Authors:  S Motomura; N M Deighton; H R Zerkowski; N Doetsch; M C Michel; O E Brodde
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

View more
  15 in total

1.  Preclinical evaluation of an 18F-labelled beta1-adrenoceptor selective radioligand based on ICI 89,406.

Authors:  Marilyn P Law; Stefan Wagner; Klaus Kopka; Christiane Renner; Victor W Pike; Otmar Schober; Michael Schäfers
Journal:  Nucl Med Biol       Date:  2010-05       Impact factor: 2.408

2.  Regulation of beta-adrenoceptor density and mRNA levels in the rat heart cell-line H9c2.

Authors:  V Dangel; J Giray; D Ratge; H Wisser
Journal:  Biochem J       Date:  1996-08-01       Impact factor: 3.857

Review 3.  Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure.

Authors:  X Wang; N S Dhalla
Journal:  Mol Cell Biochem       Date:  2000-11       Impact factor: 3.396

Review 4.  Cardiac adrenergic control and atrial fibrillation.

Authors:  Antony J Workman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-04       Impact factor: 3.000

5.  Down-regulated beta-adrenoceptors in severely failing human ventricles: uniform regional distribution, but no increased internalization.

Authors:  H F Pitschner; A Droege; M Mitze; M Schlepper; O E Brodde
Journal:  Basic Res Cardiol       Date:  1993 Mar-Apr       Impact factor: 17.165

6.  The dose-related hyper-and-hypokalaemic effects of salbutamol and its arrhythmogenic potential.

Authors:  W J Du Plooy; L Hay; C P Kahler; P J Schutte; H D Brandt
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

7.  Are [O-methyl-11C]derivatives of ICI 89,406 beta1-adrenoceptor selective radioligands suitable for PET?

Authors:  Marilyn P Law; Stefan Wagner; Klaus Kopka; Victor W Pike; Otmar Schober; Michael Schäfers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-29       Impact factor: 9.236

8.  Hypertrophic cardiomyopathy: a desensitized cardiac beta-adrenergic system in the presence of normal plasma catecholamine concentrations.

Authors:  C Schumacher; H Becker; R Conrads; U Schotten; S Pott; M Kellinghaus; M Sigmund; F Schöndube; C Preusse; H D Schulte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000

9.  Reduced density and altered regulation of rat atrial L-type Ca2+ current in heart failure.

Authors:  Richard C Bond; Simon M Bryant; Judy J Watson; Jules C Hancox; Clive H Orchard; Andrew F James
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-12-06       Impact factor: 4.733

10.  Chronic myocardial infarction promotes atrial action potential alternans, afterdepolarizations, and fibrillation.

Authors:  Sarah Kettlewell; Francis L Burton; Godfrey L Smith; Antony J Workman
Journal:  Cardiovasc Res       Date:  2013-04-08       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.